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Table 1
Area under the curve (AUC) of a receiver operating characteristics (ROC) of PBL
inﬂammatory gene expression for distinguishing radiographic progressors from
non-progressors in the OAI cohort. For multivariable models, we used 10-fold
stratiﬁed cross-validation repeated with 100 different splits of data into different
splits of data into 10-folds.
Progressors (JSN>0.0mm)
vs.non-Progressors
(JSN<0.0mm)
AUC CI P value
IL-1b 0.750 0.66e0.84 0.0000
TNFa 0.674 0.58e0.77 0.0002
COX-2 0.621 0.52e0.72 0.0095
IL-1b þ TNFa þ COX-2 0.611 0.51e0.71 0.0170
Progressors (JSN>0.2mm)
vs non-Progressors
(JSN<0.0mm)
AUC CI P value
IL-1b 0.755 0.06 - 0.65 0.0000
TNFa 0.674 0.57 - 0.73 0.0002
COX-2 0.614 0.50 - 0.72 0.0204
IL-1b þ TNFa þ COX-2 0.719 0.62 e 0.82 0.0000
Progressors (JSN>0.5mm)
vs non-Progressors
(JSN<0.0mm)
AUC CI P value
IL-1b 0.758 0.65e0.87 0.0000
TNFa 0.675 0.56e0.79 0.0015
COX-2 0 611 0.49e0.73 0.0382
IL-1b þ TNFa þ COX-2 0.730 0.62e0.84 0.0000
Abstracts / Osteoarthritis and Cartilage 23 (2015) A26eA81A52progressors in the OAI cohort. Similar to the NYUHJD cohort, elevated
expression of IL-1b, TNFa and COX-2 mRNA distinguished radiographic
progressors from non-progressors (Table 1). PBL IL-1b expression found
to be strongest predictor of all three radiographic progressors. In mul-
tivariate models that combine all three markers did not improve upon
IL-1b predictivity. We thus conclude that either the signal in TNFa and
Cox-2 is already subsumed by IL-1b and/or that it is not easy to capture
the non-overlapping signals without increasing the sample size (i.e.,
ﬁtting a stronger multivariate predictor will require more sample size).
Conclusions: We identiﬁed, and conﬁrmed in two cohorts, increased
inﬂammatory gene expression (IL-1, TNFa or COX-2) by PBLs that pre-
dict radiographic progression in patients with SKOA. The data indicate
that inﬂammatory events within joint tissues of patients with SKOA are
reported in the peripheral blood. These PBL transcriptome signals of
local joint inﬂammation merit further study as potential biomarkers for
OA disease progression.
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CHANGES IN ARGS-AGGRECAN, C-TERMINAL TYPE II AND N-
TERMINAL TYPE I COLLAGEN TELOPEPTIDES, AND CYTOKINE
CONCENTRATIONS OVER FIVE YEARS AFTER ANTERIOR CRUCIATE
LIGAMENT INJURY
A. Struglics y, S. Larsson y, N. Kumahashi y,z, R. Frobell y,
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Musculoskeletal Function and Physiotherapy and Dept. of Orthopaedics
and Traumatology, University of Southern Denmark, DenmarkTable 1
Correlation analysis between biomarkers. Spearman’s rank order correlation (p-values) b
avoid repeated observations, each subject contributed samples at one time point only. S
Synovial ﬂuid ARGS Serum
Synovial ﬂuid IL-6 0.479 (<0.001) 0.130
Synovial ﬂuid IL-8 0.409 (<0.001) 0.089
Synovial ﬂuid IL-10 0.492 (<0.001) 0.073
Synovial ﬂuid IFN-g 0.460 (<0.001) 0.257
Synovial ﬂuid NF-a 0.438 (<0.001) 0.075
Synovial ﬂuid ARGS e 0.359
Serum ARGS e
Urine CTX-II
Urine NTX-IPurpose: Rupture of the anterior cruciate ligament (ACL) leads to an
increased risk of developing knee osteoarthritis (OA). Mechanisms
behind this development are not fully understood, and analysis of
biomarkers could be used for elucidating these biological processes but
also to detect and predict joint pathology and post traumatic OA. We
prospectively monitored levels of synovial ﬂuid and serum pro-
inﬂammatory cytokines and aggrecan ARGS neoepitope, and urine C-
terminal type II (CTX-II) and N-terminal type I (NTX-I) collagen telo-
peptides over ﬁve years after ACL rupture.
Methods: Synovialﬂuid, serumandurinewere collected from121 adults
at baseline (0-6weeks after injury),16, 30and52weeks, and twoandﬁve
years after an acute ACL injury (the KANON trial, ISRCTN 84752559,
http://www.controlled-trials.com). Reference samples: synovial ﬂuid (n
¼ 21), serum (n ¼ 23) and urine (n ¼ 62) were from knee healthy vol-
unteers. Synovialﬂuid and serumconcentrations of interleukin (IL)-6, IL-
8, IL-10, interferon (IFN)-g, and tumor necrosis factor (TNF)-a were
measured by a multiplex immunoassay from Meso Scale Discovery
(MSD), and ARGS-aggrecan was analyzed by an in-house immunoassay
assay. Urine levels of CTX-II and NTX-I were measured by ELISA assays
from IDS and Osteomark, and were corrected for urine creatinine levels
(CREP2, Roche). Concentrations of cytokines, ARGS-aggrecan and colla-
gen telopeptides were not normally distributed. We used Mann-Whit-
ney tests for group comparisons and Spearman’s rank test (rS) for
correlation analysis. To estimate time until the synovial ﬂuid biomarker
concentrations had decreased to half that of the value at baseline
(‘concentration half-life’) amixedvariance componentsmodelwas used.
Results: At baseline (0-6 weeks after injury), synovial ﬂuid cytokine
concentrations were elevated 6- (TNF-a, p < 0.001), 7- (IL-8, p < 0.001),
13- (IFN-g, p < 0.001), 21- (IL-10, p < 0.001) and 1050-fold (IL-6, p <
0.001) compared to knee healthy reference levels. This increase was not
observed in serum cytokine concentrations. Synovial ﬂuid and serum
ARGS-aggrecan, and urine CTX-II concentrations were elevated 8- (p <
0.001), 1.4- (p ¼ 0.002) and 1.5-fold (p ¼ 0.009) respectively, while
baseline urine NTX-I levels were no different from the reference. At time
periods after baseline, concentrations of synovial ﬂuid cytokines and
ARGS-aggrecan, and urine CTX-II and NTX-I decreased rapidly, where
ARGS-aggrecan and cytokines showed the following statistically sig-
niﬁcant mean concentration half-lives, in years: IL-6 0.9, IL-8 2.2, IL-10
2.3, IFN-g 3.1, TNF-a 3.6, ARGS-aggrecan 4.0. Five years after injury, the
synovial ﬂuid TNF-a concentration was still higher (1.7-fold, p ¼ 0.044)
than the reference level, the urine NTX-I level was lower (0.5-fold, p <
0.001), while the concentration of the other markers were at the same
level as seen in references. Over the ﬁve year period, there was a cor-
relation between synovial ﬂuid and serum ARGS-aggrecan concen-
trations (rS ¼ 0.36, p < 0.001), and between serum and synovial ﬂuid
ARGS-aggrecan and urine CTX-II levels (rS ¼ 0.36, p < 0.001 and rS ¼
0.26, p ¼ 0.006, respectively) (Table 1). Synovial ﬂuid cytokine con-
centrations correlated with synovial ﬂuid ARGS-aggrecan level (rS ¼
0.41 to 0.49, p < 0.001) and with levels of urine collagen telopeptides (rS
¼ 0.21 to 0.31, p ¼ 0.001 to 0.028) (Table 1).
Conclusions: Acute ACL injury induced high levels of proinﬂammatory
cytokines in the joint which were associated with proteolysis of
aggrecan and type II collagen. This trauma induced joint inﬂammation
persisted many years after ACL injury, and together with the reduction
of bone turnover, seen several years after injury as decreased urine NTX-
I levels, may eventually result in permanent cartilage damage and the
development of post traumatic OA.etween biomarkers in different body ﬂuids from ACL injured subjects (n ¼ 121). To
tatistically signiﬁcant correlations are in bold. ARGS, ARGS neoepitope of aggrecan.
ARGS Urine CTX-II Urine NTX-I
(0.173) 0.263 (0.006) 0.211 (0.028)
(0.353) 0.276 (0.004) 0.181 (0.059)
(0.443) 0.264 (0.006) 0.146 (0.129)
(0.006) 0.309 (0.001) 0.278 (0.003)
(0.434) 0.297 (0.002) 0.232 (0.015)
(<0.001) 0.258 (0.006) 0.112 (0.243)
0.356 (<0.001) 0.086 (0.353)
- 0.691 (<0.001)
e
